A new registry-based study sheds light on patient factors that may influence risk of breast cancer associated with use of postmenopausal hormone replacement therapy (HRT)-including race, weight, and breast density. Findings from the report, published in The Journal of the National Cancer Institute, suggest the greatest association between HRT use and breast cancer in women with low/normal body mass index (BMI) and extremely dense breasts.
A new registry-based study sheds light on patient factors that may influence risk of breast cancer associated with use of postmenopausal hormone replacement therapy (HRT)-including race, weight, and breast density. Findings from the report, published in The Journal of the National Cancer Institute, suggest the greatest association between HRT use and breast cancer in women with low/normal body mass index (BMI) and extremely dense breasts.
Data for the study, by researchers from the University of Chicago, were from the Breast Cancer Surveillance Consortium, a longitudinal registry of mammography screening in the United States. The analysis included 164,824 screening mammograms from 9300 breast cancer cases in postmenopausal women aged 45 and older. Missing data on HRT use and other covariables were accommodated by using multiple imputation methods.
The researchers used logistic regression to estimate the odds ratio (OR) for breast cancer associated with HRT use and stratify it by race/ethnicity, age, BMI, and breast density. Two-way interaction terms between HRT use and each key covariable of interest were part of the computations. P values for possible interactions were computed from Wald z statistics and all statistical tests were two-sided.
Use of HRT was associated with >20% increased risk of breast cancer in white (OR=1.21; 95% CI = 1.14-1.28), Asian (OR=1.58; 95% CI = 1.18-2.11), and Hispanic women (OR=1.35; 95% CI=1.09-1.67) but not black women (OR=0.91; 95% CI = 0.72-1.14). The highest risk of breast cancer with HRT use was seen in women with low/normal BMI and extremely dense breasts (OR=1.48; 95% CI = 1.21=1.83) compared with nonusers. No excess risk of breast cancer was associated with HRT use in overweight/obese women with less-dense breasts (adjusted ORs=0.96-1.03). Risk stratification, the researchers concluded, could be of help to clinicians in counseling women about use of HRT for menopausal symptoms.
To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary Ob/Gyn Special Delivery.
OASIS-1 trial reports reduced VMS frequency and severity from elinzanetant
May 17th 2024A recent study showcased at the 2024 ACOG Annual Clinical & Scientific Meeting unveils elinzanetant's efficacy in alleviating vasomotor symptoms, sleep disturbances, and enhancing menopause-related quality of life in postmenopausal women.
Read More
Postmenopausal urinary incontinence treatment data found lacking
May 6th 2024Discover the findings of a comprehensive study exploring the efficacy of various treatments for postmenopausal urinary incontinence, shedding light on the current research gap and recommending avenues for future investigation.
Read More
Pioglitazone outperforms metformin in IVF for PCOS-related infertility
May 6th 2024A recent double-blind, randomized clinical trial revealed a higher clinical pregnancy rate with pioglitazone compared to metformin in polycystic ovarian syndrome patients undergoing in vitro fertilization, suggesting potential for improved outcomes.
Read More